Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Genetic influences on cognitive decline in Parkinson's disease.

Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A.

Mov Disord. 2012 Apr;27(4):512-8. doi: 10.1002/mds.24946. Epub 2012 Feb 16.

2.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

3.

Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ; ICICLE-PD study group., Barker RA.

Brain. 2014 Oct;137(Pt 10):2743-58. doi: 10.1093/brain/awu201. Epub 2014 Jul 30.

4.

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA.

Brain. 2009 Nov;132(Pt 11):2958-69. doi: 10.1093/brain/awp245. Epub 2009 Oct 7.

PMID:
19812213
5.

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA.

J Neurol. 2009 Mar;256(3):493-8. doi: 10.1007/s00415-009-0119-8. Epub 2009 Mar 18.

PMID:
19308307
6.

Association between apolipoprotein E ε4 and longitudinal cognitive decline: nested case-control study among chinese community-dwelling elders.

Ma F, Wang J, Miao R, Zhao W, Wang Q.

Neuropsychobiology. 2011;64(2):102-9. doi: 10.1159/000324991. Epub 2011 Jun 21.

PMID:
21701228
7.

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; Parkinson Study Group DATATOP Investigators., Zhang J.

Parkinsonism Relat Disord. 2015 Mar;21(3):271-6. doi: 10.1016/j.parkreldis.2014.12.027. Epub 2015 Jan 5.

8.

APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

Paul KC, Rausch R, Creek MM, Sinsheimer JS, Bronstein JM, Bordelon Y, Ritz B.

J Parkinsons Dis. 2016 Apr 2;6(2):349-59. doi: 10.3233/JPD-150762.

PMID:
27061069
9.

Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.

Białecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, Gorzkowska A, Budrewicz S, Mak M, Jarosz M, Gołąb-Janowska M, Koziorowska-Gawron E, Droździk M, Sławek J.

Pharmacogenet Genomics. 2012 Oct;22(10):716-24. doi: 10.1097/FPC.0b013e32835693f7.

PMID:
22890010
10.

Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population.

Qiu C, Winblad B, Fratiglioni L.

Neurol Res. 2006 Sep;28(6):650-6.

PMID:
16945218
11.

Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status.

Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA.

Parkinsonism Relat Disord. 2014 May;20(5):503-7. doi: 10.1016/j.parkreldis.2014.02.001. Epub 2014 Feb 13.

12.

Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease.

Tröster AI, Fields JA, Paolo AM, Koller WC.

J Neurol Sci. 2006 Oct 25;248(1-2):62-7.

PMID:
16769085
13.
14.

What can biomarkers tell us about cognition in Parkinson's disease?

Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D.

Mov Disord. 2014 Apr 15;29(5):622-33. doi: 10.1002/mds.25846. Review.

15.

Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease.

Ezquerra M, Campdelacreu J, Gaig C, Compta Y, Muñoz E, Martí MJ, Valldeoriola F, Tolosa E.

Neurosci Lett. 2008 Dec 19;448(1):20-3. doi: 10.1016/j.neulet.2008.10.018. Epub 2008 Oct 10.

PMID:
18930114
16.

The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment.

Di Maria E, Cammarata S, Parodi MI, Borghi R, Benussi L, Galli M, Galimberti D, Ghidoni R, Gonella D, Novello C, Pollero V, Perroni L, Odetti P, Scarpini E, Binetti G, Tabaton M.

J Alzheimers Dis. 2010;19(3):909-14. doi: 10.3233/JAD-2010-1285.

PMID:
20157246
17.

The effect of MAPT H1 and APOE ε4 on transition from mild cognitive impairment to dementia.

Samaranch L, Cervantes S, Barabash A, Alonso A, Cabranes JA, Lamet I, Ancín I, Lorenzo E, Martínez-Lage P, Marcos A, Clarimón J, Alcolea D, Lleó A, Blesa R, Gómez-Isla T, Pastor P.

J Alzheimers Dis. 2010;22(4):1065-71. doi: 10.3233/JAD-2010-101011.

PMID:
20930301
18.

Effects of COMT, DRD2, BDNF, and APOE Genotypic Variation on Treatment Efficacy and Cognitive Side Effects of Electroconvulsive Therapy.

Bousman CA, Katalinic N, Martin DM, Smith DJ, Ingram A, Dowling N, Ng C, Loo CK.

J ECT. 2015 Jun;31(2):129-35. doi: 10.1097/YCT.0000000000000170.

PMID:
25148110
19.

APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment.

Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan E, Gibson A, Kalaria RN, Kenny RA.

Neurology. 2004 Oct 26;63(8):1399-402.

PMID:
15505155
20.

Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.

Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C.

Dement Geriatr Cogn Disord. 2006;22(1):73-82. Epub 2006 May 12.

PMID:
16699282

Supplemental Content

Support Center